世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

血漿分画市場:製品毎(免疫グロブリン大量療法、アルブミン、抗血友病因子、フォンヴィレブランド因子、PCC、プロテアーゼ阻害因子)、用途毎(免疫学、血液学、救命救急、リウマチ学、)、エンドユーザ毎(病院、診療所、学術機関) - 2024年までの世界市場予測

Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2019年3月US$5,650
シングルユーザライセンス
301 317

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の血漿分画市場に関する調査レポートです。

“Global plasma fractionation market is projected to grow at a CAGR of 6.6%.”

The global plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. Growth in the plasma fractionation market can largely be attributed to factors such as the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

“By product, immunoglobulin market is expected to hold the largest share of the plasma fractionation market in 2019.”

The immunoglobulin segment is expected to dominate the plasma fractionation market during the forecast period. IVIg is the most extensively used plasma product across the globe, meant for the treatment of dermatomyositis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. The growing prevalence of these and other target diseases, as a result, is the key driver of market growth.

“Factor VIII will dominate the coagulation factor concentrates market in 2019.”

The coagulation factor market is segmented into factor VIII, factor IX, Von Willebrand factor, prothrombin factor concentrates, fibrinogen concentrates, and factor XIII. Factor VIII segment is expected to hold the largest share in the coagulation factor concentrates market in 2019. This is attributed to the growth in geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies for a majority of hemophilia patients in developing countries is also expected to drive this market.  

“North America is expected to hold the largest share during the forecast period (2019–2024)”

North America is expected to dominate the plasma fractionation market during the forecast period. The demand for plasma products in North America is mainly driven by the increasing use of immunoglobulins in neurological and autoimmune diseases and the increasing use of prophylaxis treatments among diagnosed patients. The rising number of registered hemophilic patients (as illustrated in the table below) is also propelling the growth of this market. The growing number of hemophilic patients will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America.

A breakdown of supply-side primary participants is mentioned below:

• By Company Type: Tier 1–38%, Tier 2–21%, and Tier 3–41%
• By Designation: C-level–30%, Director Level–28%, Others–42%
• By Region: North America–35%, Europe–25%, Asia Pacific–20%, Latin America–12%, Middle East and Africa-8%

Major players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).

Research Coverage:

The plasma fractionation market in this report is segmented by product, application, end user, and region. It provides detailed information regarding the major factors influencing the growth market (drivers, restraints, opportunities, and industry-specific challenges). The study tracks and analyzes competitive developments (such as partnerships, agreements, collaborations, mergers & acquisitions, product developments, geographical expansions, and R&D activities) and strategically profiles the key players and comprehensively analyzes their market shares and core competencies in the plasma fractionation market.

Reasons to buy this report:

From an insight perspective, this research report has focused on various levels of analysis—the market share analysis of top players in the global market, different product segments, as well on the regional levels, company profiles that comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the plasma fractionation market; high-growth regions; and market drivers, restraints, and opportunities. The report provides the latest statistics and industry trends, allowing buyers to identify high-growth product segments and potential customers and suppliers, hence driving revenue growth and profitability. The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on products offered by the top players in the global plasma fractionation market

• Product Development/Innovation: Detailed insights on growth strategies, research & development activities, and product launches in the global plasma fractionation market

• Market Development: Comprehensive information about lucrative emerging markets–the report analyzes the markets for plasma fractionation across regions

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global plasma fractionation market

• Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global plasma fractionation market
 



目次

1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 SCOPE OF THE STUDY 25
1.3.1 MARKETS COVERED 25
1.3.2 YEARS CONSIDERED FOR THE STUDY 26
1.4 CURRENCY 26
1.5 STAKEHOLDERS 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH APPROACH 27
2.1.1 SECONDARY SOURCES 28
2.1.1.1 Key data from secondary sources 28
2.1.2 PRIMARY SOURCES 29
2.1.2.1 Primary sources 29
2.1.2.2 Key data from primary sources 30
2.1.2.3 Key industry insights 31
2.2 MARKET SIZE ESTIMATION 32
2.2.1 BOTTOM-UP APPROACH 33
2.2.2 TOP-DOWN APPROACH 33
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
2.4 MARKET SHARE ESTIMATION 35
2.5 ASSUMPTIONS FOR THE STUDY 35
2.6 LIMITATIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 41
4.1 PLASMA FRACTIONATION MARKET OVERVIEW 41
4.2 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET 42
4.3 PLASMA FRACTIONATION MARKET: REGIONAL MIX 43
4.4 PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS. DEVELOPED COUNTRIES 44

5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 45
5.2.1 MARKET DRIVERS 45
5.2.1.1 Growing use of immunoglobulins in various therapeutic areas 45
5.2.1.2 Rising geriatric population across the globe 48
5.2.1.3 Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin 48
5.2.1.4 Increase in plasma collection 49
5.2.2 MARKET RESTRAINTS 51
5.2.2.1 High cost and limited reimbursement 51
5.2.2.2 Emergence of recombinant alternatives 52
5.2.3 MARKET OPPORTUNITIES 52
5.2.3.1 Rising prevalence of bleeding disorders 52
5.2.4 MARKET CHALLENGES 53
5.2.4.1 Stringent government regulations 53
6 INDUSTRY INSIGHTS 54
6.1 INTRODUCTION 54
6.2 KEY INDUSTRY TRENDS 55
6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES 56
6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS 57
6.2.3 RISING ADOPTION OF SCIG 57
6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS 58
6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA 58
6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS 60
6.3 PORTER’S FIVE FORCES 62
6.3.1 THREAT OF NEW ENTRANTS 62
6.3.2 THREAT OF SUBSTITUTES 63
6.3.3 BARGAINING POWER OF SUPPLIERS 63
6.3.4 BARGAINING POWER OF BUYERS 64
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 64
6.4 VENDOR BENCHMARKING 65
6.4.1 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET 65
6.4.2 NO. OF PLASMA COLLECTION CENTERS AND FRACTIONATION CAPACITIES, BY KEY PLAYER 67
6.4.3 BUSINESS PRESENCE OF KEY PLAYERS IN THE VALUE CHAIN 67
6.5 PRICING ANALYSIS 68

7 PLASMA FRACTIONATION MARKET, BY PRODUCT 69
7.1 INTRODUCTION 70
7.2 IMMUNOGLOBULINS 71
7.2.1 INTRAVENOUS IMMUNOGLOBULINS 73
7.2.1.1 IVIg holds the largest share of the immunoglobulins market 73
7.2.2 SUBCUTANEOUS IMMUNOGLOBULINS 76
7.2.2.1 Benefit of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market 76
7.2.3 OTHER IMMUNOGLOBULINS 78
7.3 COAGULATION FACTOR CONCENTRATES 82
7.3.1 FACTOR VIII 85
7.3.1.1 Factor VIII holds the largest share of the coagulation factor concentrates market 85
7.3.2 FACTOR IX 88
7.3.2.1 Growth in the aging population and the rise in the number of hemophilic patients is expected to drive the growth in this market 88
7.3.3 VON WILLEBRAND FACTOR 91
7.3.3.1 Market growth is primarily driven by the increasing prevalence and diagnosis of Von Willebrand disease and hemophilia 91
7.3.4 PROTHROMBIN COMPLEX CONCENTRATE 93
7.3.4.1 Advantages of PCC over fresh frozen plasma will support market growth in this segment 93
7.3.5 FIBRINOGEN CONCENTRATES 95
7.3.5.1 Safety profile, accuracy, and speed of administration have supported the growth of the fibrinogen concentrates market 95
7.3.6 FACTOR XIII 96
7.3.6.1 Applications in treating rare bleeding disorders will contribute to the demand for Factor XIII 96
7.4 ALBUMIN 98
7.4.1 WIDE DEMAND FOR ALBUMIN AS AN ANTIOXIDANT AND VOLUME EXPANDER WILL DRIVE MARKET GROWTH 98
7.5 PROTEASE INHIBITORS 101
7.5.1 INCREASING GLOBAL DISEASE BURDEN WILL DRIVE DEMAND FOR PROTEASE INHIBITORS 101
7.6 OTHER PRODUCTS 102
8 PLASMA FRACTIONATION MARKET, BY APPLICATION 104
8.1 INTRODUCTION 105
8.2 NEUROLOGY 106
8.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE THIS MARKET 106
8.3 IMMUNOLOGY 109
8.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS TO DRIVE THE GROWTH OF THIS MARKET 109

8.4 HEMATOLOGY 112
8.4.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS 112
8.5 CRITICAL CARE 115
8.5.1 INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS 115
8.6 PULMONOLOGY 117
8.6.1 RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY 117
8.7 HEMATO-ONCOLOGY 119
8.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS IN HEMATO-ONCOLOGY 119
8.8 RHEUMATOLOGY 121
8.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY 121
8.9 OTHER APPLICATIONS 122
9 PLASMA FRACTIONATION MARKET, BY END USER 124
9.1 INTRODUCTION 125
9.2 HOSPITALS & CLINICS 126
9.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWTH IN THE NUMBER OF HOSPITALS & CLINICS—KEY FACTORS DRIVING GROWTH 126
9.3 CLINICAL RESEARCH LABORATORIES 128
9.3.1 INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE THE MARKET FOR CLINICAL RESEARCH LABORATORIES 128
9.4 ACADEMIC INSTITUTES 130
9.4.1 INCREASING BASIC MEDICAL RESEARCH ACTIVITIES AND GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES 130
10 PLASMA FRACTIONATION MARKET, BY REGION 132
10.1 INTRODUCTION 133
10.2 NORTH AMERICA 136
10.2.1 US 140
10.2.1.1 The US dominates the global plasma fractionation market 140
10.2.2 CANADA 144
10.2.2.1 Canada is one of the world's highest per capita users of IVIg 144
10.3 EUROPE 148
10.3.1 GERMANY 154
10.3.1.1 Germany has the highest plasma fractionation capacity in Europe 154
10.3.2 FRANCE 158
10.3.2.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France 158

10.3.3 ITALY 161
10.3.3.1 Growth in the country’s geriatric population to drive the market for plasma fractionation 161
10.3.4 SPAIN 165
10.3.4.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth 165
10.3.5 UK 168
10.3.5.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK 168
10.3.6 REST OF EUROPE 172
10.4 ASIA PACIFIC 175
10.4.1 CHINA 180
10.4.1.1 Significant growth in the incidence of diseases such as hypoalbuminemia, liver cancer, and hepatitis B are driving the growth of plasma-derived products market in China 180
10.4.2 JAPAN 184
10.4.2.1 The rising geriatric population is expected to increase the prevalence of neurological disorders and hematological diseases in Japan in the coming years 184
10.4.3 AUSTRALIA 188
10.4.3.1 High production of plasma products and the growing demand for plasma products for the treatment of chronic disease to drive market growth 188
10.4.4 INDIA 193
10.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth 193
10.4.5 VIETNAM 196
10.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth 196
10.4.6 INDONESIA 200
10.4.6.1 Growing government initiatives to drive market growth 200
10.4.7 MALAYSIA 204
10.4.7.1 Growing healthcare awareness, increasing prevalence of bleeding disorders, and the rising geriatric population are the major factors driving market growth 204
10.4.8 REST OF ASIA PACIFIC 207
10.5 LATIN AMERICA 211
10.5.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES, RISING GERIATRIC POPULATION, AND INCREASING INCIDENCE OF BLEEDING DISORDERS TO DRIVE MARKET GROWTH IN LATIN AMERICA 211
10.6 MIDDLE EAST & AFRICA 214
10.6.1 TURKEY 218
10.6.1.1 Turkey dominated the plasma fractionation market in the Middle East and Africa 218
10.6.2 SAUDI ARABIA 222
10.6.2.1 Rising use of immunoglobulins in neurology and immunology and the strengthening of healthcare infrastructure to drive market growth 222
10.6.3 EGYPT 226
10.6.3.1 Growing research on plasma and plasma derivatives and the increasing adoption of plasma products to drive market growth 226
10.6.4 UAE 230
10.6.4.1 Increasing incidence of bleeding disorders and growing government initiatives for healthcare infrastructure development to drive market growth 230
10.6.5 REST OF MIDDLE EAST AND AFRICA 233
11 COMPETITIVE LANDSCAPE 236
11.1 OVERVIEW 236
11.2 MARKET SHARE ANALYSIS 238
11.2.1 MARKET SHARE ANALYSIS, BY PRODUCT,2018 241
11.2.1.1 Immunoglobulin market, by key players 241
11.2.1.1.1 IVIG market, by key players 241
11.2.1.2 Coagulation factor market, by key players 242
11.2.1.2.1 Factor VIII market, by key players 242
11.2.1.3 Albumin market, by key players 243
11.2.2 MARKET SHARE ANALYSIS, BY REGION,2018 243
11.2.2.1 North America plasma fractionation market, by key players 243
11.2.2.1.1 US plasma fractionation market, by key players 244
11.2.2.2 Europe plasma fractionation market, by key players 244
11.3 COMPETITIVE LEADERSHIP MAPPING 245
11.3.1 VISIONARY LEADERS 245
11.3.2 INNOVATORS 245
11.3.3 DYNAMIC DIFFERENTIATORS 245
11.3.4 EMERGING COMPANIES 246
11.4 COMPETITIVE SCENARIO AND TRENDS 247
11.4.1 PRODUCT LAUNCHES/APPROVALS 247
11.4.2 EXPANSIONS 247
11.4.3 ACQUISITIONS 248
11.4.4 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS 249

12 COMPANY PROFILES 250
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1 CSL 250
12.2 GRIFOLS 254
12.3 SHIRE 259
12.4 OCTAPHARMA 263
12.5 KEDRION 266
12.6 LFB 270
12.7 BIOTEST 273
12.8 SANQUIN 277
12.9 CHINA BIOLOGIC PRODUCTS 279
12.10 BIO PRODUCTS LABORATORY (BPL) 282
12.11 JAPAN BLOOD PRODUCTS ORGANIZATION 284
12.12 GC PHARMA (GREEN CROSS CORPORATION) 286
12.13 SHANGHAI RAAS BLOOD PRODUCTS 289
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 291
13.1 INSIGHTS OF INDUSTRY EXPERTS 291
13.2 DISCUSSION GUIDE 292
13.3 AVAILABLE CUSTOMIZATION 296
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 297
13.5 RELATED REPORT 299
13.6 AUTHOR DETAILS 300

 

LIST OF TABLES

TABLE 1 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS 45
TABLE 2 ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG 46
TABLE 3 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION, 2017 47
TABLE 4 NUMBER OF PATIENTS TREATED FOR TOP 10 TARGET CONDITIONS IN THE
UK (2015-16) 47
TABLE 5 INCREASE IN GERIATRIC POPULATION FROM 2000 TO 2050 ACROSS THE GLOBE 48
TABLE 6 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2018 51
TABLE 7 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2017 53
TABLE 8 FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYERS 56
TABLE 9 PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2014) 59
TABLE 10 CHINA: TOP PLAYERS IN THE PLASMA FRACTIONATION MARKET, 2018 59
TABLE 11 MAJOR LOCAL PLAYERS IN CHINA 60
TABLE 12 REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON PLASMA-DERIVED PRODUCTS 61
TABLE 13 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS,
BY PLAYER (2018) 68
TABLE 14 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS,
BY REGION (2018) 68
TABLE 15 PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 70
TABLE 16 IVIG VS. SCIG THERAPY 71
TABLE 17 IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 72
TABLE 18 IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 72
TABLE 19 INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS 74
TABLE 20 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 75
TABLE 21 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY REGION,
2017–2024 (METRIC TONS) 75
TABLE 22 SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS 77
TABLE 23 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 77
TABLE 24 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY REGION,
2017–2024 (METRIC TONS) 78
TABLE 25 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS 79
TABLE 26 OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 81
TABLE 27 OTHER IMMUNOGLOBULINS MARKET, BY REGION,
2017–2024 (MILLION INTERNATIONAL UNITS) 82
TABLE 28 COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 83
TABLE 29 COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 84
TABLE 30 FACTOR VIII OFFERED BY KEY MARKET PLAYERS 86
TABLE 31 FACTOR VIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 87
TABLE 32 FACTOR VIII MARKET, BY REGION, 2017–2024 (MILLION INTERNATIONAL UNITS) 87
TABLE 33 FACTOR IX OFFERED BY KEY MARKET PLAYERS 89
TABLE 34 FACTOR IX MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 90
TABLE 35 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS 91
TABLE 36 VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 92
TABLE 37 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS 93
TABLE 38 PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 94
TABLE 39 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS 95
TABLE 40 FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 96
TABLE 41 FACTOR XIII OFFERED BY KEY MARKET PLAYERS 97
TABLE 42 FACTOR XIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 97
TABLE 43 ALBUMIN OFFERED BY KEY MARKET PLAYERS 98
TABLE 44 ALBUMIN MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 100
TABLE 45 GLOBAL ALBUMIN MARKET, BY REGION, 2017–2024 (METRIC TONS) 100
TABLE 46 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS 101
TABLE 47 PROTEASE INHIBITORS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 102
TABLE 48 OTHER PRODUCTS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 103
TABLE 49 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 105
TABLE 50 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030 106
TABLE 51 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY 107
TABLE 52 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 108
TABLE 53 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY 109
TABLE 54 PRIMARY IMMUNODEFICIENCY DISEASE, BY TYPE 110
TABLE 55 PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION,
2013 VS. 2015 110
TABLE 56 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY 111
TABLE 57 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 111
TABLE 58 NUMBER OF HEMOPHILIA PATIENTS (2012–2017) 112
TABLE 59 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY 114
TABLE 60 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 114
TABLE 61 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE 115
TABLE 62 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY,
2017–2024 (USD MILLION) 116
TABLE 63 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY 117
TABLE 64 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 118
TABLE 65 INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN LYMPHOMA,
BY REGION, 2012 VS. 2015 VS. 2018 119
TABLE 66 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY 119
TABLE 67 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 120
TABLE 68 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY,
2017–2024 (USD MILLION) 121
TABLE 69 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS 122
TABLE 70 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 123
TABLE 71 PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION) 125
TABLE 72 PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017–2024 (USD MILLION) 127
TABLE 73 CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN (2017) 128
TABLE 74 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES,
BY COUNTRY, 2017–2024 (USD MILLION) 129
TABLE 75 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2017–2024 (USD MILLION) 131
TABLE 76 REGIONAL DISTRIBUTION OF PLASMA FRACTIONATION PLANTS AND PLASMA THROUGHPUT, BY REGION, 2014 133
TABLE 77 PLASMA FRACTIONATION MARKET, BY REGION, 2017–2024 (USD MILLION) 135
TABLE 78 NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017 136
TABLE 79 TRANSFER OF PLASMA FROM US TO OTHER REGIONS, 2014 136
TABLE 80 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 138
TABLE 81 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 138
TABLE 82 NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 138
TABLE 83 NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 139
TABLE 84 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 139
TABLE 85 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 140
TABLE 86 US: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 142
TABLE 87 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 142
TABLE 88 US: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 142
TABLE 89 US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 143
TABLE 90 US: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 143
TABLE 91 US: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION) 144
TABLE 92 CANADA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 145
TABLE 93 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 145
TABLE 94 CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 146
TABLE 95 CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 146
TABLE 96 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 147
TABLE 97 CANADA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 147
TABLE 98 EUROPE: PLASMA COLLECTION, 2007–2016 148
TABLE 99 PLASMA FRACTIONATION PLANTS IN EUROPE (2017) 149
TABLE 100 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 151
TABLE 101 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 151
TABLE 102 EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 152
TABLE 103 EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 152
TABLE 104 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 153
TABLE 105 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 153
TABLE 106 GERMANY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 155
TABLE 107 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 155
TABLE 108 GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 156
TABLE 109 GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 156
TABLE 110 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 157
TABLE 111 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 157
TABLE 112 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2017 158
TABLE 113 FRANCE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 159
TABLE 114 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 159
TABLE 115 FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 159
TABLE 116 FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 160
TABLE 117 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 160
TABLE 118 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 161
TABLE 119 ITALY: NUMBER OF BLOOD DONATIONS, 2011 VS. 2013 161
TABLE 120 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018-E, & 2023-E) 162
TABLE 121 ITALY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 162
TABLE 122 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 163
TABLE 123 ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 163
TABLE 124 ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 163
TABLE 125 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 164
TABLE 126 ITALY: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 164
TABLE 127 SPAIN: KEY MACROINDICATORS FOR THE PLASMS FRACTIONATION MARKET 165
TABLE 128 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 166
TABLE 129 SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 166
TABLE 130 SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 166
TABLE 131 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 167
TABLE 132 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 167
TABLE 133 USAGE OF IMMUNOGLOBULINS 168
TABLE 134 ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS
IN THE UK, 2012–2016 169
TABLE 135 VOLUME OF IMMUNOGLOBULINS USED FOR THE TOP 5 DIAGNOSES (2016) 169
TABLE 136 UK: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 170
TABLE 137 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 170
TABLE 138 UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 170
TABLE 139 UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 171
TABLE 140 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 171
TABLE 141 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION) 172
TABLE 142 TOTAL NUMBER OF HEMOPHILIA PATIENTS IN REST OF EUROPE: 2012–2017 173
TABLE 143 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 173
TABLE 144 ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 174
TABLE 145 ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 174
TABLE 146 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 175
TABLE 147 ROE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 175
TABLE 148 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 177
TABLE 149 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 177
TABLE 150 ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 178
TABLE 151 ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 178
TABLE 152 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 179
TABLE 153 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 179
TABLE 154 CHINA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 181
TABLE 155 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 181
TABLE 156 CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 182
TABLE 157 CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 182
TABLE 158 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 183
TABLE 159 CHINA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 183
TABLE 160 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN,
2014 VS. 2017 (IN IU/TOTAL POPULATION) 184
TABLE 161 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2017 184
TABLE 162 JAPAN: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 185
TABLE 163 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 185
TABLE 164 JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 186
TABLE 165 JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 186
TABLE 166 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 187
TABLE 167 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 187
TABLE 168 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2006–2015 188
TABLE 169 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD
AND BLOOD PRODUCTS, 2008–2017 (USD MILLION) 189
TABLE 170 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017) 190
TABLE 171 AUSTRALIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 190
TABLE 172 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 190
TABLE 173 AUSTRALIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 191
TABLE 174 AUSTRALIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 191
TABLE 175 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 192
TABLE 176 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 192
TABLE 177 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2016 193
TABLE 178 INDIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 194
TABLE 179 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 194
TABLE 180 INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 194
TABLE 181 INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 195
TABLE 182 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 195
TABLE 183 INDIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 196
TABLE 184 VIETNAM: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 198
TABLE 185 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 198
TABLE 186 VIETNAM: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 198
TABLE 187 VIETNAM: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 199
TABLE 188 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 199
TABLE 189 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 200
TABLE 190 INDONESIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 202
TABLE 191 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 202
TABLE 192 INDONESIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 202
TABLE 193 INDONESIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 203
TABLE 194 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 203
TABLE 195 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 204
TABLE 196 MALAYSIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2017 205
TABLE 197 MALAYSIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 205
TABLE 198 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 205
TABLE 199 MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 206
TABLE 200 MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 206
TABLE 201 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 207
TABLE 202 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 207
TABLE 203 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 208
TABLE 204 REST OF ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 209
TABLE 205 REST OF ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 209
TABLE 206 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 210
TABLE 207 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 210
TABLE 208 BRAZIL: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 211
TABLE 209 MEXICO: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 212
TABLE 210 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 212
TABLE 211 LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 212
TABLE 212 LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION) 213
TABLE 213 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 213
TABLE 214 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 214
TABLE 215 HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA, 2012–2017 214
TABLE 216 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION)
IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2017 215
TABLE 217 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 215
TABLE 218 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 216
TABLE 219 MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 216
TABLE 220 MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 217
TABLE 221 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 217
TABLE 222 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 218
TABLE 223 TURKEY: DEMOGRAPHIC INDICATORS 218
TABLE 224 TURKEY: REPORTED CASES OF BLOOD DISORDERS, 2012 VS. 2014 219
TABLE 225 TURKEY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 219
TABLE 226 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 220
TABLE 227 TURKEY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 220
TABLE 228 TURKEY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 220
TABLE 229 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 221
TABLE 230 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 221
TABLE 231 ESTIMATED INCIDENCE AND PREVALENCE OF CID, SCID, AND MHC II DEFICIENCY IN CHILDREN IN SAUDI ARABIA 222
TABLE 232 PER CAPITA CONSUMPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND ALBUMIN (2015/2016) 223
TABLE 233 SAUDI ARABIA: BLOOD DISORDER CASES, BY TYPE, 2014 VS. 2016 223
TABLE 234 SAUDI ARABIA: KEY MACROINDICATORS FOR THE PLASMA
FRACTIONATION MARKET 223
TABLE 235 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 224
TABLE 236 SAUDI ARABIA: IMMUNOGLOBULINS MARKET, BY TYPE,
2017–2024 (USD MILLION) 224
TABLE 237 SAUDI ARABIA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2017–2024 (USD MILLION) 224
TABLE 238 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 225
TABLE 239 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 225
TABLE 240 EGYPT: BLOOD DISORDER CASES, BY TYPE, 2014–2017 226
TABLE 241 EGYPT: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 227
TABLE 242 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 227
TABLE 243 EGYPT: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 228
TABLE 244 EGYPT: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 228
TABLE 245 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 229
TABLE 246 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION)  229
TABLE 247 UAE: GROWTH IN THE NUMBER OF BLOOD DONORS 230
TABLE 248 UAE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET 230
TABLE 249 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 231
TABLE 250 UAE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 231
TABLE 251 UAE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION) 231
TABLE 252 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 232
TABLE 253 UAE: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 232
TABLE 254 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST AND AFRICA,
2012 VS. 2017 233
TABLE 255 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII IN SOUTH AFRICA AND QATAR (IU/TOTAL POPULATION), 2013 VS. 2017 233
TABLE 256 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 234
TABLE 257 ROMEA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION) 234
TABLE 258 ROMEA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2017–2024 (USD MILLION)  234
TABLE 259 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 235
TABLE 260 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER,
2017–2024 (USD MILLION) 235
TABLE 261 GROWTH STRATEGY MATRIX 238
TABLE 262 PRODUCT LAUNCHES/APPROVALS, JANUARY 2016 TO APRIL 2019 247
TABLE 263 EXPANSIONS, JANUARY 2016 TO APRIL 2019 247
TABLE 264 ACQUISITIONS, JANUARY 2016 TO APRIL 2019 248
TABLE 265 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2016 TO APRIL 2019 249

 

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 27
FIGURE 2 SUPPLY SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 31
FIGURE 3 DEMAND SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 32
FIGURE 4 DATA TRIANGULATION METHODOLOGY 34
FIGURE 5 IMMUNOGLOBULINS SEGMENT TO DOMINATE THE PLASMA FRACTIONATION MARKET, BY PRODUCT, FROM 2019 TO 2024 37
FIGURE 6 NEUROLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 38
FIGURE 7 PLASMA FRACTIONATION MARKET, BY END USER, 2019 VS. 2024 (USD MILLION) 38
FIGURE 8 GEOGRAPHIC SNAPSHOT: PLASMA FRACTIONATION MARKET IN 2018 39
FIGURE 9 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH 41
FIGURE 10 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE PLASMA FRACTIONATION MARKET IN 2018 42
FIGURE 11 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 43
FIGURE 12 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD 44
FIGURE 13 GLOBAL PERCENTAGE OF DEATHS FROM RESPIRATORY DISEASES, 2008 TO 2030 49
FIGURE 14 SOURCE PLASMA COLLECTION IN THE US, 2004–2017 50
FIGURE 15 PLASMA COLLECTION CENTERS IN THE US AND EUROPE, 2007–2016 50
FIGURE 16 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE,
2012–2017 52
FIGURE 17 INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS 55
FIGURE 18 PLASMA FRACTIONATION MARKET IN CHINA VS. US, 2017–2024 58
FIGURE 19 PORTER’S FIVE FORCES ANALYSIS 62
FIGURE 20 IMMUNOGLOBULIN SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024 70
FIGURE 21 PREVALENCE OF BLEEDING DISORDERS, BY COUNTRY, 2017 83
FIGURE 22 MEAN PER CAPITA USAGE OF FACTOR VIII (2016 VS 2017) 85
FIGURE 23 MEAN PER CAPITA USAGE OF FACTOR IX (2016 VS 2017) 88
FIGURE 24 NEUROLOGY SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024 105
FIGURE 25 NUMBER OF HEMOPHILIA PATIENTS IN MAJOR COUNTRIES, 2016 VS. 2017 113
FIGURE 26 HOSPITALS & CLINICS TO REGISTER THE HIGHEST CAGR DURING
THE FORECAST PERIOD 125
FIGURE 27 NORTH AMERICA TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 134
FIGURE 28 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 135
FIGURE 29 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT 137
FIGURE 30 PLASMA COLLECTION VOLUME IN THE US, 2004–2017 140
FIGURE 31 PLASMA COLLECTION CENTERS IN THE US, 2005–2017 141
FIGURE 32 EUROPE: PLASMA FRACTIONATION MARKET SNAPSHOT 150
FIGURE 33 HEMOPHILIA A & B PATIENTS IN GERMANY, 2013–2016 154
FIGURE 34 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT 176
FIGURE 35 FRESH BLOOD EXPENDITURE IN AUSTRALIA, 2008–2017 (USD MILLION) 189
FIGURE 36 MEAN PER CAPITA USE OF FACTOR VIII AND IX IN VIETNAM,
2014–2017 (IU/POPULATION) 197
FIGURE 37 PATIENT POPULATION SUFFERING FROM BLEEDING DISORDERS
IN VIETNAM, 2014–2017 197
FIGURE 38 BLOOD DONATION IN INDONESIA, 2011–2015 (MILLION UNITS) 201
FIGURE 39 KEY STRATEGIES ADOPTED BY PLAYERS (JANUARY 2016 TO APRIL 2019) 237
FIGURE 40 PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 239
FIGURE 41 COMPETITIVE LEADERSHIP MAPPING 246
FIGURE 42 CSL: COMPANY SNAPSHOT (2018) 250
FIGURE 43 GRIFOLS: COMPANY SNAPSHOT (2017) 254
FIGURE 44 SHIRE: COMPANY SNAPSHOT (2017) 259
FIGURE 45 OCTAPHARMA: COMPANY SNAPSHOT (2018) 263
FIGURE 46 KEDRION: COMPANY SNAPSHOT (2017) 266
FIGURE 47 LFB: COMPANY SNAPSHOT (2016) 270
FIGURE 48 BIOTEST: COMPANY SNAPSHOT (2017) 273
FIGURE 49 SANQUIN: COMPANY SNAPSHOT (2017) 277
FIGURE 50 CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2017) 279
FIGURE 51 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2016) 284
FIGURE 52 GC PHARMA: COMPANY SNAPSHOT (2017) 286
 

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る